Frontline Ventures

Frazier Healthcare Partners is a Seattle-based healthcare venture capital and private equity firm founded in 1991, investing in life science and healthcare companies from seed and Series A through to growth equity stages, with a track record spanning drug discovery, medical devices, diagnostics, and healthcare services businesses. The firm has raised over $5 billion across multiple fund vehicles and invests with initial checks from $5 million to $30 million, providing the full lifecycle of institutional capital from early clinical development through commercialization. Frazier's team combines financial investment expertise with operational experience in building biotech and medical device companies, and is particularly recognized for backing clinical-stage drug development companies where deep scientific diligence and patient capital are required to navigate regulatory approval timelines. Portfolio companies include Acceleron Pharma, the biopharmaceutical company developing treatments for serious and rare diseases, which was acquired by Bristol-Myers Squibb for $11.4 billion in 2021; Achaogen, the antibiotic-focused company that filed for bankruptcy in 2019 after commercial challenges; Editas Medicine, the CRISPR genome editing therapy company that completed a Nasdaq IPO in 2016; and Forma Therapeutics, the clinical-stage company developing treatments for rare hematologic diseases that was acquired by Novo Nordisk for $1.1 billion in 2022. Beyond its original investments in Acceleron, Achaogen, Editas, and Forma Therapeutics, the broader portfolio includes dozens of additional clinical-stage biopharmaceutical and medical device companies.